iTeos Therapeutics annonce de nouvelles données de Phase 1/2a indiquant l’activité antitumorale de l’inupadénant, son antagoniste du récepteur A2A de l’adénosine, lors de l’ASCO 2021

NEXT STORY
Merus présente les données cliniques sur le zenocutuzumab dans les cancers à fusion du gène NRG1 (NRG1+) lors de l’assemblée annuelle 2021 de l’American Society of Clinical Oncology (ASCO) (résumé oral)
PREV STORY
UPDATE – UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

author_avatar
NASDAQ Market News

argenx reports third quarter 2017 financial results and provides business update

October 26, 2017 Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ...

author_avatar
NASDAQ Market News

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

author_avatar
NASDAQ Market News